Full Year 2024 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) successfully completed the Phase 3 study for Orviglance, confirming its efficacy and safety.
- The company secured significant financial flexibility through a loan financing and a successful financing round, raising SEK105 million.
- Orviglance addresses a global market of USD800 million, with a well-defined unmet need for liver imaging in patients with impaired kidney function.
- The company is on track to submit the NDA for Orviglance by mid-2025, with a potential launch in Q2 2026.
- Ascelia Pharma AB (FRA:7ZA) has established strong relationships with key opinion leaders and scientific communities, enhancing its commercial launch prospects.
- The company faces the challenge of securing a commercialization partner, which is crucial for the successful launch of Orviglance.
- There is a risk of delays in the FDA approval process, which could impact the timeline for Orviglance's market entry.
- The financial runway is limited to late 2025, excluding the repayment of a $27.5 million loan, necessitating further financing or partnership agreements.
- Orviglance's market success depends on overcoming the established use of gadolinium-based agents, despite their associated risks.
- The company must navigate complex regulatory and strategic considerations to achieve an optimal label and market positioning for Orviglance.
Good afternoon and welcome. Today's event with Ascelia Pharma. And focus for today's event. So, of course, the Q4 and Financial year 2024 report, the company released a report this morning before the stock exchange opened. And my guest today is the Deputy CEO and the CFO Julie Waras Brogren. Okay. As always, you're more than welcome to post your questions just below the video window and then I will pass them on to Julie.
And we will record this event and after the event and after the editing, we will post it on our platform and I know you will do the same on Ascelia's platform. So with that said, I hope we get a really good event and I will hand over the microphone. I will hand over the word to, to you. You welcome you and welcome to the audience.
Yes. Thank you, Claus. It's good to be here and always good to look back at the, at a very successful year. So '24 was really a transforming year for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
